Fig. 2
From: Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia
Deterministic sensitivity analyses on total influenza cases avoided (a) and societal cost offsets (b) over the period 2002–2012 (2009 excluded). High value: results of the model when the parameter value is set to the lower bound of the parameter range. Low value: results of the model when the parameter value is set to the upper bound of the parameter range. Example of interpretation for Fig. 2b: In the base case, QIV was estimated to lead to the avoidance of $46.5 million in societal costs. When considering the lower and upper bounds of the estimated degree of B lineage cross-protection, cost offsets were estimated to be A$ 66.2 million and A$ 26.8 million respectively. Lower and higher bounds used in the deterministic sensitivity analyses are available in Additional file 1. Abbreviations: GP: general practitioner; TIV: trivalent influenza vaccine